1. Home
  2. BHK vs REPL Comparison

BHK vs REPL Comparison

Compare BHK & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Core Bond Trust

BHK

Blackrock Core Bond Trust

HOLD

Current Price

$9.49

Market Cap

679.6M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$9.95

Market Cap

721.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHK
REPL
Founded
2001
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
679.6M
721.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BHK
REPL
Price
$9.49
$9.95
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$12.00
AVG Volume (30 Days)
188.3K
1.7M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
8.34%
N/A
EPS Growth
N/A
N/A
EPS
1.03
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.02
$2.68
52 Week High
$11.09
$14.80

Technical Indicators

Market Signals
Indicator
BHK
REPL
Relative Strength Index (RSI) 41.99 57.76
Support Level $9.45 $9.63
Resistance Level $9.56 $10.29
Average True Range (ATR) 0.07 0.59
MACD 0.00 -0.10
Stochastic Oscillator 23.08 35.68

Price Performance

Historical Comparison
BHK
REPL

About BHK Blackrock Core Bond Trust

Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: